Profil
Leah Monteiro is currently the Vice President of Investor Relations & Communications at Solid Biosciences, Inc. Prior to her current position, she worked as the Senior Director of Communications & IR at KalVista Pharmaceuticals, Inc. from 2016 to 2021.
She also served as the Vice President of Investor Relations at DURECT Corp.
and as the Senior Manager of Investor Relations at Genzyme Corp.
Additionally, she worked as the Manager of Corporate Communications at Sesen Bio, Inc.
Aktive Positionen von Leah Monteiro
| Unternehmen | Position | Beginn |
|---|---|---|
| SOLID BIOSCIENCES INC. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Leah Monteiro
| Unternehmen | Position | Ende |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Investor Relations Kontakt | 01.12.2021 |
| CARISMA THERAPEUTICS, INC. | Investor Relations Kontakt | 01.07.2016 |
| DURECT CORPORATION | Investor Relations Kontakt | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| SOLID BIOSCIENCES INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
